TITLE OF INVENTION:

SYNTHESIS, AND PHOTODYNAMIC THERAPY-MEDIATED ANTI-CANCER, AND OTHER USES OF CHORIN *E*6-TRANSFERRIN.

5

CROSS REFERENCE TO RELATED APPLICATIONS: None

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR

DEVELOPMENT: This invention was not directly supported by any federally

10   sponsored research.

REFERENCE TO SEQUENCE LISTING, TABLES, OR COMPUTER PROGRAM

LISTINGS: None

15

BACKGROUND OF THE INVENTION:

Rapidly growing cells require continuous intracellular iron transport in order to

divide. Free iron, or iron salts, are absent in biological systems as iron salts can catalyze

many un-favorable reactions (Conrad and Umbreit, 2000). Therefore, all iron delivery,

20   storage, and transport in cells and higher organisms occurs while the iron is complexed to

proteins.   The major circulating iron transport protein is transferrin (Tf), which exists in

blood at levels of 200 - 400 mg/100 ml (Ponka and Richardson, 1998). Each transferrin

protein binds and transports two atoms of iron. To accomplish iron internalization, cells

express transferrin receptors (TfR; Testa, et. al., 1993; Ponka, et. al., 1998; Ponka and

Lok, 1999) on their surface. These receptors interact with transferrin and two iron-

saturated transferrins bind to one TfR. This TfR-Tf complex is internalized into the cell

and the complexed iron is delivered to needed sites.   Most tumor cells exhibit rapid

growth rates and therefore internalize copious quantities of iron and express high levels

5   of transferrin receptors (Gatter et. al., 1983; Niitsu et. al., 1987). Quiescent normal adult

cells express little or no TfR (Gatter et. al., 1983; Tani et. al., 2000; Juhlin, 1989; Niitsu

et. al., 1987) . Therefore, in many tissue areas, if a tumor exists, the only site of high TfR

expression will be associated with the tumor cells. The expression of TfR in human

tumor cells has been found to correlate with tumor grade, stage, progression, and

10   metastasis. This has been seen in breast carcinomas (Wrba et. al., 1986), bladder

transitional cell carcinomas (Seymour, et. al., 1987), and malignant melanoma (Van

Muijen et. al., 1990). In addition, high levels of TfR have been observed in a metastatic

lesion of a maxillary neoplasm, but not in the parental tumor (Yoda et. al., 1994),and the

expression of TfR was higher in a human melanoma line selected for metastatic

15   capability in nude mice than in the poorly metastatic tumor cells of the parental

population (Van Muijen, et. al., 1991). In other studies, growth response to Tf was seen

to correlate with metastatic progression in the B16 melanoma (Stackpole et. al., 1994)

and Tf was identified as the major bone-marrow derived mitogen for bone-marrow

metastasizing prostatic carcinoma cells (Rossi et. al., 1992). We have found that tumor

20   cell expression of TfR can correlate with the metastatic ability of certain tumor cells

(Cavanaugh and Nicolson, 1991, 1998; Cavanaugh et. al., 1999), which indicates that

heightened TfR expression can be associated with the more aggressive tumor cell types.

Therapy against cancer is ideal when cancer cells are specifically killed while normal cells are left largely intact. Furthermore, an ideal treatment is achieved when cell killing occurs only at the site of the tumor and any non-specific killing at other sites is avoided entirely. To achieve these ends, researchers designing anti-cancer therapies will

5   direct cancer cell killing agents at cell components which are novel to cancer cells or are present at much greater numbers on cancer cells than on normal cells. Various toxin-conjugated or radioactive antibodies directed towards antigens expressed only on the surface of cancer cells have been produced and tested (Hudson, 1999; Scott and Welt, 1997). Strategies to combat cancer using reagents directed at the transferrin/TfR system

10   are currently being explored, and these are most successful when used to treat tumors of hematopoetic origin (Elliot et. al., 1988; Kemp et. al., 1992, 1995; Kovar et. al., 1995). The problem with any agent of this nature is that they can act, albeit to a lesser degree, on normal cells nearby and distant from the tumor site, causing side effects. To circumvent the latter problem, treatments have been devised which attack cancer only at the site of

15   the tumor. If a pre-toxin could be specifically delivered to the TfR, and could furthermore be specifically activated to the toxin state at a certain site, then a tumor cell specific, site specific killing of tumor cells could be achieved. If at the same time, the pre-toxin remained non-toxic at other sites where the activation was not performed, then side effects could be avoided.

20   Photodynamic therapy (PDT) is an anti-cancer strategy that has been the subject of intensive study in recent years (Hsi et. al., 1999). The idea is to deliver to a tumor site a an inactive toxin which is then activated to a cell-killing toxin by exposure to light. Site-specific light irradiation causes site-specific cell killing. A number of different

compounds which become toxic when impinged upon by light have been developed (Hsi

et. al., 1999). These compounds have been conjugated to various proteins (Akhlynina et.

al., 1995; Donald et. al., 1991; Gijsens and De Witte, 2000; Del Governatore et. al., 2000

) or covalently linked to other molecules (Katsumi et.al., 1994; Bachor et. al., 1991), to

5   create a complex that when delivered *in vivo*, will produce a tumoricidal effect, when the

tumor area is irradiated with light. One of the more useful PDT agents is chlorin *e6*, a

nettle-derived porphyrin which is rendered toxic by irradiation with visible light.

We sought to conjugate transferrin with chlorin *e6* , to develop an anti-cancer

PDT agent which would exploit the high affinity of tumor cells for transferrin and the

10   site-specific nature of PDT. Transferrin has been suggested as a delivery vehicle for

anticancer drugs (Singh, 1999) and non-chlorin *e6* PDT conjugates of transferrin have

been produced (Hamblin and Newman, 1994). However, follow-up studies and extensive

in vitro or *in vivo* work with the latter have been lacking.

The conjugation of chorin e6 to proteins usually occurs in solution with

15   compounds such as EDC (1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide

hydrochloride) or cyclohexyl-3(2-morpholinoethyl) carbodiimide being present to

activate chlorin e6 carbonyl groups to amine-reactive entities (Akhlynina et. al., 1995;

Bachor et. al., 1991). With EDC, chorin e6 carboxyl groups form 0-acylisourea

intermediates for their conjugation to protein primary amines. Typically, once reactions

20   are complete, conjugated proteins are separated from un-reacted intermediate and chlorin

e6 by gel filtration. A number of these procedures were used to conjugate chorin *e6* to

transferrin with apparent success at conjugate formation, however the conjugate made

using these methods consistently displayed none of transferrin's usual growth stimulating

activity on a particular target cell line.   When conjugation using EDC was performed

after immobilization of Tf to QAE-sepharose, biological activity of the ligand was

maintained. The conjugated protein could be released from the gel by high salt only if a

detergent such as CHAPS was present. Tf conjugated with chorin e6 in this fashion

5   displayed cell growth-promoting activity, TfR binding activity, and displayed potent

light-dependent killing of tumor cells in culture. As such, this patent and the invention is

for this novel method for the conjugation of proteins to chorin *e6*, and for the subsequent

use of this conjugate as a tumor-specific, tumor site-activatable, anti-cancer agent.

BACKGROUND REFERENCES:

U.S. Patent Documents:

5

5,528,453	November, 1993	Koopecek, et. al.
5,876,989	March, 1999	Berg, et. al.
5,976,535	November, 1999	Fritzberg, et. al.
6,107,466	August, 2000	Hasan, et. al.

10

Specific Documents:

Akhlynina, T.V., Rosenkranz, A.A., Jans, D.A., Sobolev, A.S. Insulin-mediated

intracellular targeting enhances the photodynamic activity of chlorin e6. *Cancer Res.*

15   *55*:1014-1019 1995.

Bachor, R., Shea, C.R., Gillies, R., Hasan, T. Photosensitized destruction of human

bladder carcinoma cells treated with chlorin e6-conjugated microspheres. *Proc Natl

Acad Sci U S A* 88:1580-1584 1991.

Cavanaugh, P.G. and Nicolson, G. L. Lung derived growth factor that stimulates the

20   growth of lung-metastasizing tumor cells: Identification as transferrin.   Journal of

Cellular Biochemistry *47*:261-271, 1991.

Cavanaugh, P.G., and Nicolson, G.L. The selection of a metastatic rat mammary

adenocarcinoma cell line from a low metastatic parental population by an in vitro

process based on cellular ability to proliferate in response to transferrin. Journal of

25   Cellular Physiology. *174:* 48-57 1998.

Cavanaugh, P.G., Jia, L., and Nicolson, G.L.   Transferrin receptor overexpression

enhances transferrin responsiveness and the metastatic growth of a rat mammary

adenocarcinoma cell line.   Breast Cancer Research and Treatment *56*:203-217, 1999.

Conrad, M.E., and Umbreit, J.N.   Iron absorption and transport-an update. *Am J Hematol*

64:287-298, 2000.

Del Governatore, M., Hamblin, M.R., Shea, C.R., Rizvi, I., Molpus, K.G., Tanabe, K.K.,

and Hasan, T.   Experimental photoimmunotherapy of hepatic metastases of colorectal

5   cancer with a 17.1Å chlorin(e6) immunoconjugate. *Cancer Res.*   60:4200-4205,

2000.

Donald, P.J., Cardiff, R.D., He, D.E., Kendall, K.   Monoclonal antibody-porphyrin

conjugate for head and neck cancer: the possible magic bullet. *Otolaryngol Head*

Neck Surg 105:781-787 1991.

10   Elliot, R. L., Stjernholm, R., and Elliot, M. C. Preliminary evaluation of platinum

transferrin (MTPC-63) as a potential nontoxic treatment for breast cancer. Cancer

Detect. Prev. 12: 469-480, 1988

Gatter, K.C., Brown, G., Trowbridge, I.S., Woolston, R.E., Mason, D.Y.   Transferrin

receptors in human tissues: their distribution and possible clinical relevance. *J Clin*

15   *Pathol*   36: 539-545. 1983.

Gijsens, A., De Witte, P.   Targeting of chlorine E6 by EGF increasing its photodynamic

activity in selective ways. *Verh K Acad Geneeskd Belg* 62:329-352, 2000.

Hamblin, M.R., and Newman, E.L. Photosensitizer targeting in photodynamic therapy. I.

conjugates of haematoporphyrin with albumin and transferrin. J. Photochem

20   Photobiol B. 26: 45-56, 1994.

Hudson, P.J. Recombinant antibody constructs in cancer therapy. *Curr Opin Immunol*

11:548-557, 1999.

Hsi, R.A., Rosenthal, D.I., Glatstein, E. Photodynamic therapy in the treatment of cancer:
current state of the art. *Drugs* 57:725-734 1999.

Katsumi, T., Aizawa, K., Okunaka, T., Kuroiwa, Y., Li, Y., Saito, K., Konaka, C., and
Kato, H. Photodynamic therapy using a diode laser with mono-L-aspartyl chorin e6
for implanted fibrosarcoma in mice. Jpn J Cancer Res. 85:1165-1170, 1994.

Kemp, J.D., Smith, K.M., Mayer, J.M., Gomez, F., Thorson, J.A., and Naumann, P.W.
Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells.
Pathobiology 60:27-32, 1992.

Kemp, J. D., Cardillo, T., Stewart, B. C., Kehrberg, S. E., Weiner, G., Hedlund, B., and
Naumann, P. W.   Inhibition of lymphoma growth *in vivo* by combined treatment with
hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against
the transferrin receptor. Cancer Res. 55: 3817-3824, 1995.

Kovar, J., Naumann, P.W., Stewart, B.C., and Kemp, J.D. Differing sensitivity of non-
hematopoetic human tumors to synergistic anti-transferrin receptor monoclonal
antibodies and deferoxamine in vitro. *Pathobiology* 63: 65-70, 1995.

Niitsu, Y., Kohgo, Y., Nishisato, T., Kondo, H., Kato, J., Urushizaki, Y., and Urushizaki,
I. Transferrin receptors in human cancerous tissues. *Tohoku J Exp Med* 153:239-243,
1987.

Ponka, P., Beaumont, C., and Richardson, D.R. Function and regulation of transferrin and
ferritin. *Seminars in Hematology* 35: 35-54, 1998.

Ponka, P., and Lok, C.N. The transferrin receptor: role in health and disease. *Int J
Biochem Cell Biol* 31: 1111-1137, 1999.

Rossi, M. C. and Zetter, B. R.   Selective stimulation of prostatic carcinoma cell proliferation by transferrin. *Proc. Natl. Acad. Sci. USA*, 89: 6197-6201, 1992.

Scott, A.M., Welt, S. Antibody-based immunological therapies. *Curr Opin Immunol* 9:717-722, 1997.

5   Seymour, G. J., Walsh, M. D., Lavin, M. F., Strutton, G., and Gardiner, R. A. Transferrin receptor expression by human bladder transitional cell carcinomas. *Urol. Res.* 15: 341-344, 1987.

Singh, M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 5:443-451, 1999.

10   Stackpole CW, Kalbag SS, Groszek L: Acquisition of in vitro growth autonomy during B16 melanoma malignant progression is associated with autocrine stimulation by transferrin and fibronectin. In Vitro Cell Dev Biol 31: 244-251, 1995

Testa, U., Pelosi, E., and Peschle, C. The transferrin receptor. Crit. Rev. Oncog., 4:241-276, 1993.

15   Van Muijen, G. N., Ruiter, D. J., Hoefakker, S. and Johnson J. P. Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker for metastasis. J. Invest. Dermatol. 95: 65-69, 1990.

Van Muijen, G. N. P., Jansen, K. F. J., Cornelissen, I. M. H. A., Smeets, D. F. C. M., Beck, J. L. M., and Ruiter, D. J. Establishment and characterization of a human

20   melanoma cell line (MV3) which is highly metastatic in nude mice. Int. J. Cancer 48: 85-91, 1991.

Wrba, F., Ritzinger, E., Reiner, A., and Holzner, J. H.   Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis.   An immunohistochemical study.   Virchows Arch. 41: 69-73, 1986.

Yoda, J., Yamanaka, N., Saito, T., Samukawa, T., Tamura, S., and Kawaguchi, T. Characterization of cell lines from metastatic maxillary cancer. Journal of the Oto-Rhino-Laryngological Society of Japan 97: 419-429, 1994.

5

BRIEF SUMMARY OF THE INVENTION:

Human iron-saturated transferrin was bound to quaternary-amino ethyl (QAE) sephadex in a buffer of 25 mM sodium phosphate, pH 7.2, containing 2 mM of the detergent CHAPS (PB/CHAPS buffer). The gel was washed free of unbound transferrin

5   and was reacted directly with 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and the porphyrin chlorin e6, in the same buffer. Or, chorin e6 was reacted with EDC in a separate vessel, in the PB/CHAPS buffer, and unreacted chorin e6 removed from the mixture by adsorption to QAE-sephadex, all in PB/CHAPS. This latter soluble EDC-modified chlorin e6 was added to the immobilized transferrin to produce

10   the immobilized conjugate. In either case, the transferrin was conjugated while bound to the gel and was washed free of un-reacted soluble conjugation components. The conjugate was then released from the gel by treatment with PB/CHAPS containing 0.5 M NaCl. The conjugate was dialyzed against PB for further use.

The conjugate was first shown to retain transferrin's growth promoting activity on

15   the rat MTLn3 tumor line, in a low serum growth assay.   The conjugate was then tested for its ability to compete with FITC-transferrin for binding to the transferrin receptor, using a western blot-mediated ligand binding assay. The conjugate was seen to possess an altered migratory pattern when analyzed by native gel electrophoresis. Finally, the conjugate was seen to kill tissue cultured tumor cells in a light-exposure dependent

20   fashion. This killing effect was not evident in the absence of light or when excess un-conjugated transferrin was present, indicating a specific effect. Chlorin e6-transferrin prepared in this manner retains biological activity and is a candidate for use as a photodynamic therapy treatment of cancer and other disorders.

The invention presents a novel method for the conjugation of a porphyrin to a

protein, in particular, the conjugation of chlorin e6 to transferrin. This results in the

formation of a relatively tumor-specific ligand which possesses cell killing activity when

activated by photodynamic therapy. Although the use of transferrin as an anti-tumor

5   photodynamic therapy agent has been discussed by others, the use of chlorin e6, the use

of this conjugation technique, and an illustration of putative effect as presented here is

not evident in the scientific or patent literature.

BRIEF DESCRIPTION OF THE DRAWINGS:

Figure 1. A: Schematic of chorin e6. B: Schematic of the reaction of chlorin e6, EDC, and transferrin.

5

Figure 2. Effect of chorin e6 on the growth of Rat MTLn3 mammary adenocarcinoma cells. Cells were plated at 2,000 cells/well in 96 well plates in $\propto$MEM containing 5% FBS. One day after plating, media was changed to $\propto$MEM containing 0.3% FBS. Increasing levels of human holo-Tf (Native Tf) or human Ce6-Tf (both in PBS) were

10   added to respective wells, in the amount indicated. Four days later, cells were quantitated using a crystal violet stain assay, where A590 correlates with cell number. **A:** an image of the crystal violet stained plate used in the assay is shown. **B:** A plot of the absorbances from A. Cell number and is seen to rise as the cells are exposed to increasing levels of native human Tf. A similar, albeit slightly lower rise was seen with

15   Ce6-Tf, indicating intact biological activity in the latter.

Figure 3. Native gel electrophoretic analysis of Ce6-Tf. 10 μg quantities of all proteins listed were treated, loaded, and run out using the native gel system. The gel was fixed and stained with Coomassie blue. The results indicate a greater mobility of chlorin e6-

20   transferrin (lanes 5 and 6) when compared to native transferrin (lane 4).

Figure 4. Competition of FITC-Tf binding to cell surfaces by Ce6-Tf. Transferrin solvent, human Ce6-Tf, or native human Tf were added to Rat MTLn3 mammary

adenocarcinoma cell monolayers equilibrated to 4° C. The final concentration of both

transferrins was 1mg/ml. FITC- human Tf was then added to all wells at 100 µg/ml.

After a 2h incubation, cells were washed, lysed, electrophoresed, blotted, and examined

for FITC content by incubation with anti-FITC and an HRP-conjugated second antibody,

5   followed by ECL. A strong band at 70,000 Kd was seen from cell lysates which received

FITC-Tf only (lanes 4 and 5), indicating FITC-Tf binding to the cells. Both Ce6-Tf

(lanes 6 and) and native Tf (lane 8) competed out the FITC-Tf as indicated by the

absence of any FITC signal in lysates from cells treated with either. Lanes 1-3 were

loaded with known amounts of pure FITC-Tf, for standardization. An image of the ECL

10   X-ray film is shown. The results indicate functional binding of Ce6-Tf to the transferrin

receptor.

Figure 5. Light-dependent killing of rat MTLn3 mammary adenocarcinoma cells by Ce6-

Tf. This was a continuous exposure, serum-free assay performed using protocol A

15   described in the cell killing section. Cells were plated in 24 well plates and grown to

confluency in αMEM containing 5% v/v FBS. On day one, media was changed to

αMEM only and increasing levels of Ce6-Tf were added to test wells to a final

concentration from 1.25 to 5.0 µg/ml. Native Tf was added to control wells at 5.0 µg/ml.

On days 2, 3, and 4, cells were exposed to light from an X-ray film box for 15 min.

20   Media and all Tf was changed each day. On day five, all cells were quantitated using the

crystal violet stain assay. Images of the stained plates are shown in **A.** Stained cell

numbers were evaluated using a Bio-Rad Multi-imager. The results of image analysis are

shown in **B,** where ODU/mm2 correlates with cell number. Results indicate a light-

dependent killing as plates kept in the dark during the process displayed no loss of cell

numbers.

Figure 6. Light-dependent killing of MTLn3 and NRK cells by Ce6-Tf. This was a one-

5   day exposure, serum-containing assay performed using protocol B described in the cell

killing section. Cells were plated in 24 well plates and grown to confluency. On day

one, media was changed and increasing levels of Ce6-Tf were added to test wells to a

final concentration from 7.5 to 30 ug/ml. Native Tf was added to control wells at

30ug/ml. On day 2, media was changed to that without added Ce6-Tf or Tf. On days 2,

10   3, and 4, cells were exposed to light from an X-ray film box for 15 min. Media was

changed each day. On day five, all cells were fixed, stained, and quantitated using the

crystal violet stain assay. Stained cell numbers were evaluated using a Bio-Rad Multi-

imager. Images of the stained plates are shown in **A** and **B.** The results of image

analysis are shown in **C** and **D**, where ODU/mm2 correlates with cell number. Results

15   indicate a light-dependent killing as plates maintained in the dark during the process

displayed no loss of cell numbers. The MTLn3 cell line was more susceptible to the

effects of the Ce6-Tf as it showed a decrease in cell numbers at the 15 ug/ml dose

whereas the normal NRK line did not.

20   **Figure 7.** Light-dependent killing of Human MCF7 breast cancer cells by Ce6-Tf. This

was a one-day exposure, serum-containing assay performed using protocol B described in

the cell killing section. Cells were plated in 24 well plates and grown to confluency. On

day one, media was changed and increasing levels of Ce6-Tf were added to test wells to a

final concentration from 7.5 to 30 ug/ml. Native Tf was added to control wells at

30ug/ml. On day 2, media in all wells was changed to that without added Ce6-Tf or Tf.

On days 2, 3, and 4, cells were exposed to light from an X-ray film box for 15 min.

Media was changed each day. On day five, all cells were fixed, stained, and quantitated

5   using the crystal violet stain assay. Stained cell numbers were evaluated using a Bio-Rad

Multi-imager. Images of the stained plates are shown in **A**. The results of image analysis

are shown in **B**, where ODU/mm2 correlates with cell number. Results indicate a light-

dependent killing as plates kept in the dark during the process displayed no loss of cell

numbers. As with the rat lines studied previously, this human line was also shown to be

10   susceptible to a combination of Ce6-Tf and light.

Figure 8. A: Effect of Ce6 alone on the viability of Rat MTLn3 cells. Cells were tested

as per method B outlined in the cell killing procedure description. Confluent cells in

αMEM containing 5% FBS were exposed to the indicated concentrations of Ce6, Ce6-

15   Tf, or Tf alone. One day later, media was changed to that without added Ce6-Tf or Tf,

and all cells were exposed to light for 15 min. This was repeated on days two and three.

Cells were then fixed and stained with Coomassie blue. An image of the stained wells is

shown. The results indicate that Ce6 alone had no cell killing effect. **B:** Effect of

excess Tf on the killing effect of Ce6-Tf. Cells were set up similarly as above, except

20   that treatments consisted of Ce6-Tf, or Ce6-Tf in conjunction with 500 or 1,000 μg/ml

native Tf. Light exposure, media changes, and cell staining were carried out as in A. An

image of the stained wells is shown. The results indicate that excess native Tf

diminished the killing effect of Ce6-Tf, indicating that the latter acts through a Tf-

specific process.

DETAILED DESCRIPTION OF THE INVENTION:

Synthesis of chorin e6-transferrin: QAE sephadex A-50 (Sigma Chemical) was hydrated

fully in water at a ratio of 1:100 (gel:water; w:v). The suspension was centrifuged at

5   1,000 X g for 5 min and the gel pellet equilibrated in 50 volumes of phosphate buffer

(PB; 20 mM Na2HPO4, pH adjusted to 7.4 with KH2PO4). The gel was re-centrifuged

and equilibrated in 10 volumes of phosphate buffer containing 2 mM CHAPS (3-[(3-

cholidamidopropyl) dimethylammonio]-1-propane-sulfonate; buffer = PB/CHAPS).

This was centrifuged at 1,000 X g for 5 min and the gel maintained in a minimal volume

10 of PB/CHAPS. Iron-saturated human transferrin (Sigma Chemical) was dissolved in

PB/CHAPS to a concentration of 10 mg/ml. To 2 ml of Tf solution was added 0.5 ml of

equilibrated QAE-sephadex slurry. This was mixed slowly by rocking for 30 min. The

gel was washed three times by suspension in and centrifugation from 25 ml PB/CHAPS.

To ensure saturation of the gel, the transferrin binding process was repeated. To make

15 the conjugate, to 0.5 ml of QAE-sephadex-Tf was added 0.5 ml of a 2 mg/ml chlorin *e6*

solution (Porphyrin products; Logan, Utah), dissolved in PB/CHAPS. To this was added

150 uL of 10 mg/ml EDC (1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide

hydrochloride; Pierce Chemical), dissolved in water. This mixture was rocked for 20 min

at 25° C. The mixture was centrifuged at 1,000 X g for 5 min and the supernatant

20 removed. To ensure complete conjugation, an additional 0.5 ml of chlorin *e6* and 150 uL

of EDC were added to the gel. The gel mixture was rocked again at 25° C for 25 min

and the gel was washed four times by repeated suspension in and centrifugation (1,000 X

g for 5 min) from 25 ml of PB/CHAPS. To elute the conjugated Tf, the gel was

suspended in 1ml PB/CHAPS containing 0.5 M NaCl. This was rocked for 20 min at 25°

C, centrifuged at 1,000 X g for 5 min, and the supernatant collected. The elution step

was repeated on the gel pellet and the supernatants pooled. The pooled chlorin e6-

transferrin was dialyzed overnight at 4° C against 4L of PB containing 0.15 M NaCl.

5

Additional procedure for the removal of free chlorin e6: The pooled chlorin e6-

transferrin (Ce6Tf) is dialyzed at 4° C against 25 mM sodium acetate, pH 4.8. To

eliminate remaining un-conjugated chlorin e6, the dialysate is combined with 2 ml of

packed SP-sepharose, previously equilibrated in the same buffer. This is mixed for 30

10   min at 25° C and the gel is washed three times by centrifugation from and re-suspension

in 20 ml equilibration buffer. The bound chlorin e6-transferrin is released from the gel

with 25 mM sodium phosphate, pH 7.2 ,containing 1.0 M NaCl. The released material is

combined with 1/100 volume of 1% (w/v) ferric ammonium citrate, and dialyzed against

25 mM NaH2PO4, pH 7.2. With this procedure, transferrin possesses a net positive

15   charge at a pH of 4.8, whereas un-modified (free) chlorin e6 retains a net negative

charge. Therefore,the transferrin will bind to a negatively charged matrix, and the free

chlorin e6 will not. This allows for the removal of free chlorin e6 via the washing

procedure.

20   *Additional procedure for the preliminary preparation of EDC-chorin e6:* Chlorin e6 is

dissolved at 1 mg/ml in 25 mM sodium phosphate, pH 7.2 containing 2 mM CHAPS.

One tenth volume of 10 mg/ml EDC (in water) is added and allowed to react with the

chlorin e6 at room temperature for 20 minutes. This is combined with an equal volume

of a 50% (vol/vol) slurry of QAE-sepharose suspended in and equilibrated in 25 mM

sodium phosphate, pH 7.5, containing 2 mM CHAPS. The gel-reacted chlorin e6 mixture

is allowed to react at room temperature for 20 minutes. The mixture is centrifuged at

1000 X g for 10 minutes and the modified chlorin e6 in the resulting supernatant is

5   removed and added to QAE-sepharose immobilized transferrin for production of the

conjugate as stated above. With this procedure, non EDC-reacted chlorin e6 will retain a

net negative charge and will bind to the QAE-sepharose. Chlorin e6 which has reacted

with the EDC at two or more carboxyls will possess a net positive charge and will not

bind to the QAE-sepharose. Therefore, only modified chlorin e6 will be added to the

10   protein and non-specific adherence of chlorin e6 to the QAE-sepharose-transferrin will

be avoided.

Native gel analysis of chorin e6-transferrin: The acrylamide gel solution consisted of

0.37 M Tris, 0.17 M HCl, 9.75 % w/v acrylamide, 0.25 % w/v Bis-acrylamide, 2 mM

15   CHAPS, 0.01% v/v TEMED and 0.025% w/v ammonium persulfate. This was poured

into a 15 X 15 X 0.1 cm chamber and polymerized. Samples were treated by addition of

one third volume of 1.48 M Tris, 0.68 M HCl, 8mM CHAPS, 0.01 % w/v bromophenol

blue, and 20% v/v glycerol. Samples were loaded onto the acrylamide gel and the gel

was placed into an electrophoresis chamber containing an anolyte of 20.16 M Tris, 0.01

20   N HCl. A catholyte of 0.02 M glycine and 0.01 N KOH was overlaid onto the gel and the

samples were electrophoresed at 40 mA constant current until the dye front was 1 cm

from the bottom of the gel. The gel was fixed in 40 methanol, 10% acetic acid and was

stained in fixative containing 0.2% Coomassie blue R250. The gel was destained with

fixative.

Competition binding: This measures the ability of a material to inhibit the binding of

5   FITC-transferrin to cell surfaces. FITC-Tf bound to the cells is detected by Western

blotting of cell lysates and specific antibody-based detection of FITC in those. Rat

MTLn3 mammary adenocarcinoma cells were grown to confluence in 12 well plates

using media consisting of ∝MEM containing 5% v/v fetal bovine serum (FBS). Media

was changed to ∝MEM only for 2 h an then again for overnight. The cells were

10 equilibrated to 4° C, wells were drained and 1 ml of a binding buffer consisting of

∝MEM containing 25 mM HEPES (pH 7.5) and 3 mg/ml liquid gelatin was added to all

wells. Ce6-TF to be tested was added to respective wells to a concentration of 1mg/ml.

Native human transferrin, as a known control inhibitor, was added to positive control

wells to a concentration of 1 mg/ml. Negative control wells received transferrin buffer

15 only. FITC-Tf was added to control and test wells to a concentration of 100 ug/ml.

Cells were incubated at 4° C for 2h. All wells were washed 4 times with 2 ml PBS and

cells were lysed with 0.5 ml PBS containing 2% Triton X-100, 0.1 U/ml aprotinin, and

100 µg/ml PMSF. Lysate protein was determined using the BCA assay (Pierce

Chemical). Equal protein amounts of cell lysates were treated with SDS-PAGE

20 treatment solution, were separated by SDS-PAGE, and blotted onto nitrocellulose. The

blot was blocked and FITC-TF was detected by treatment with rabbit anti-FITC then with

anti-rabbit IgG-HRP followed by ECL using an HRP substrate.

Growth assays: Rat MTLn3 mammary adenocarcinoma cells were plated at 2,000

cells/well in 96 well plates in αMEM containing 5% FBS. One day after plating, media

was changed to αMEM containing 0.3% FBS. Increasing levels of human holo-Tf or

human Ce6-Tf (both in PBS) were added to respective wells. Four days later, cells were

5   quantitated using a crystal violet stain assay.

Cell killing assays: **A:** Serum-free media assays. These were performed to initially

assess the effect of Ce6-Tf and to verify its light-dependent killing. Target cells were

grown to confluence in 24 well plates. On the day of the assay, media in all wells was

10   replaced with 1 ml of fresh serum-free media and increasing levels of Ce6-Tf added to

test wells. Native human holo-Tf was added, at the highest Ce6-Tf dose, to control wells.

B: Serum-containing, one day exposure assays. For these, serum was maintained, to

emulate *in vivo* conditions where excess endogenous normal transferrin would be

15   present. In addition, the Ce6-Tf exposure was limited to 1 day to emulate a one time

Ce6-Tf injection. Target cells were grown to confluence in 24 well plates. On the day of

the assay, media in all wells was replaced with 1 ml of fresh serum-containing media and

increasing levels of Ce6-Tf added to test wells. Native human holo-Tf was added, at the

highest Ce6-Tf dose, to control wells.   One day after Tf addition, media in all plates was

20   changed to normal culture media (without Ce6Tf).

With both assay methods, two plates for each line to be tested were plated and

treated identically.   One day after Ce6-Tf addition, test plates were exposed to the light

from an X-ray film box for 15 min. : the box was placed horizontally and the culture

plates placed directly on the cover glass. The parallel plate from a given line was kept in

the dark. The light treatment was repeated for 3 days. Media was changed (with [A] or

without [B] added Ce6-Tf) each day, to maintain cell viability. On the fourth day, the

5   cells were quantitated using a crystal violet stain assay: wells were drained and washed 4

times with 2 ml PBS; cells were fixed with 1 ml 5% v/v glutaraldehyde (in PBS) at 25° C

for 20 min.; wells were washed 4 times with 2 ml distilled water and stained with 1 ml of

a 1:1 (v:v) mixture of 0.2% (w/v) crystal violet and 100 mM CAPS (pH 9.0). Wells were

drained and washed 4 times with 2 ml distilled water. After drying, cell density was

10   determined using a Bio-Rad Multiimager, where ODU/mm2 correlates with cell number.

Transferrin competition of cell killing: These were performed to ensure that Ce6-Tf's

cell killing effect was due to the function of the transferrin ligand: that the light-induced

killing effect could be neutralized with excess native Tf. Method B. from above was

15   used. Confluent cultures of MTLn3 cells in 24 well plates were treated with 30 ug/ml of

Ce6Tf. At the time of Ce6Tf addition, certain wells also received human holo-transferrin

so that the final concentration was 0.5 or 1.0 mg/ml. One day later, media was changed

to normal culture media. Light-induced killing assays were continued and cells

quantitated as stated above in method B.

20

Effect of Ce6 alone: To determine if Ce6 alone, if added in appropriate concentrations,

would induce cell death. Gel filtration analysis indicated no significant change in Tf's

molecular weight after Ce6 conjugation (data not shown). It was assumed from this that

less than 10 molecules of Ce6 were conjugated to each Tf protein. Ce6Tf was very

active in causing light-induced cell death when initially present at 0.43 uM (30ug/ml),

so free Ce6 was added to cultures at 4.3 uM, a ten fold molar excess, to ensure that Ce6

was present in greater amounts than that encountered by cells when exposed to Ce6Tf.

5   So Ce6 was added to a final concentration of 2.5 µg/ml to confluent MTLn3 cells. Light-

induced killing assays were conducted as stated in method B above.

10